



## William Alegria

Lecturer, Medicine - Med/Infectious Diseases

### Bio

---

#### BIO

Dr. Alegria is a board-certified Infectious Diseases Pharmacotherapy specialist and antimicrobial stewardship consultant with the Stanford Antimicrobial Safety and Sustainability Program. He primarily practices in the inpatient setting and is dedicated to developing targeted stewardship interventions in immunocompromised patient populations. His clinical interests include management of infections in immunocompromised hosts, antifungal pharmacotherapy, and difficult-to-treat infections.

#### Publications (selected)

Navigating recurrent *Clostridioides difficile* infection without Bezlotoxumab: potential challenges ahead. Arya R, Zimmet AN, Holubar M, Alegria W. *Antimicrob Steward Healthc Epidemiol*. 2025

How to leverage medication use evaluations for antimicrobial stewardship goals: a primer for physicians. Prasad R, Arya R, Meng L, Holubar M, Alegria W, Zimmet AN.

*Antimicrob Steward Healthc Epidemiol*. 2025

Beyond the basics: rethinking antimicrobial stewardship by targeting cytomegalovirus immune globulin for immunocompromised patients. Prasad R, Lu B, Veloria D, Mui E, Nelson J, Dhillon G, Deresinski S, Holubar M, Alegria W. *Antimicrob Steward Healthc Epidemiol*. 2025

No "One-Size-Fits All": chronic "Carryover" diagnoses dilute antibiotic prescribing rates for sinusitis among adults in primary and urgent care settings.

Smith M, Hawkins M, Laikijrunc C, Mui E, Alegria W, Leung T, Zimmet A, Ha D, Holubar M. *Infect Control Hosp Epidemiol*. 2024

Combination Antifungal Therapy for Invasive Mucormycosis in Immunocompromised Hosts: A Single-Center Experience. Lu B, Ha D, Shen S, Ferguson Toll J, Kim A, Kim S, Mui E, Deresinski S, Holubar M, Alegria W. *Open Forum Infect Dis*. 2024

"Electronic Phenotyping" Antimicrobials to Facilitate Outpatient Stewardship for Asymptomatic Bacteriuria and Urinary Tract Infection in Renal

Transplant. Zimmet AN, Ha D, Mui E, Smith M, Hawkins M, Alegria W, Holubar M. *Open Forum Infect Dis*. 2024

Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia. Fox E, Ha D, Bounthavong M, Meng L, Mui E, Holubar M, Deresinski S, Alegria W. *BMC Infect Dis.* 2022

Shorter durations of antibiotic therapy in organ transplant. Alegria W, Medvedeva N, Holubar M. *Curr Opin Organ Transplant.* 2022

Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent. On S, Rath CG, Lan M, Wu B, Lau KM, Cheung E, Alegria W, Young R, Tan M, Kim C, Phun J, Patel N, Mannis G, Logan AC, Kennedy V, Goodman A, Taplitz RA, Young PA, Wen R, Saunders IM. *Br J Haematol.* 2022

Early Antibiotic Discontinuation or De-escalation in High-Risk Patients With AML With Febrile Neutropenia and Prolonged Neutropenia. Alegria W, Marini BL, Gregg KS, Bixby DL, Perissinotti A, Nagel J. *J Natl Compr Canc Netw.* 2022

Effect of rapid methicillin-resistant *Staphylococcus aureus* nasal polymerase chain reaction screening on vancomycin use in the intensive care unit. Diep C, Meng L, Pourali S, Hitchcock MM, Alegria W, Swayngim R, Ran R, Banaei N, Deresinski S, Holubar M. *Am J Health Syst Pharm.* 2021 Dec

The Current State of Antifungal Stewardship in Immunocompromised Populations. Alegria W, Patel PK. *J Fungi (Basel).* 2021

Bacteremia due to Methicillin-Resistant *Staphylococcus aureus*: An Update on New Therapeutic Approaches. Holubar M, Meng L, Alegria W, Deresinski S. *Infect Dis Clin North Am.* 2020

Impact of Rapid Antimicrobial Susceptibility Testing in Gram-Negative Rod Bacteremia: a Quasi-experimental Study. Hogan CA, Ebunji B, Watz N, Kapphahn K, Rigdon J, Mui E, Meng L, Alegria W, Holubar M, Deresinski S, Banaei N. *J Clin Microbiol.* 2020

Antimicrobial Stewardship in Cancer Patients: The Time is Now. Aitken SL, Nagel JL, Abbo L, Alegria W, Barreto JN, Dadwal S, Freifeld AG, Jain R, Pergam SA, Tverdek FP, Seo SK; Antimicrobial Stewardship in Cancer Consortium ASCC. *J Natl Compr Canc Netw.* 2019